Bixiye
QP71-18 Pharmacy Benefit Update - New Drug-Related Step Therapy with Quantity Limit Criteria: Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors
Taariikhda barnaamijka Dhaqangalayso Agosto 21, 2018
Natiijooyinka Raadinta
Soo bandhiga 2841 - 2850 ee natiijooyinka 3688
Bixiye
QP90-18 Addition of Drugs to the Self-Administered Oncology Agents Prior Authorization with Quantity Limit Program
Taariikhda uu dhaqangalayo Barnaamijka: Nov 14, 2018
Bixiye
QP69-18 Universal Pharmacy Policy for Minnesota Health Care Programs Subscribers - Morphine Equivalent Dose (MED) Limit Update
Taariikhda barnaamijka Dhaqangalayso Agosto 21, 2018
Bixiye
QP96-18 Clarification Regarding the use of PLUTO for Minnesota Health Care Program Subscribers Effective December 1, 2018
Taariikhda uu dhaqangalayo Barnaamijka: Nov 14, 2018
Bixiye
QP81-18 Changes to Cotiviti Mailroom Operations Center Location
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 25, 2018
Bixiye
QP78-18 Pharmacy Update - Change in Coverage for Brand Serevent Diskus 50 mcg/dose
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 11, 2018
Bixiye
QP106-18 Migration of Minnesota Health Care Programs Frequently Asked Questions (FAQ)
Taariikhda uu dhaqangalayo Barnaamijka: Des 12, 2018
Bixiye
QP109-18 Medicare Advantage Implementation Frequently Asked Questions (FAQ)
Taariikhda uu dhaqangalayo Barnaamijka: Des 12, 2018
Bixiye
QP108-18 FEP Blue Focus Members
Taariikhda uu dhaqangalayo Barnaamijka: Des 12, 2018
Bixiye
QP92-18 Addition of Drug to the Topical Lidocaine Prior Authorization with Quantity Limit Program
Taariikhda uu dhaqangalayo Barnaamijka: Nov 14, 2018